SYNPO2L Antibody

What is SYNPO2L and why is it significant in research?

SYNPO2L (synaptopodin 2-like) belongs to the synaptopodin family and functions as an actin-associated protein that modulates actin-based cellular morphology. It plays critical roles in the positive regulation of Rho protein signal transduction and stress fiber assembly . Research significance has increased due to SYNPO2L's emerging role in cancer progression, particularly in colorectal cancer metastasis . Understanding SYNPO2L's functions provides insights into cytoskeletal dynamics and potentially targetable cancer pathways.

What applications are SYNPO2L antibodies suitable for?

SYNPO2L antibodies have been validated for multiple research applications with specific recommended dilutions:

For optimal results, researchers should perform antibody titration experiments in their specific experimental systems, as reactivity may vary depending on sample type and preparation methods .

Which species do SYNPO2L antibodies typically recognize?

Commercial SYNPO2L antibodies have validated reactivity with human, mouse, and rat samples . Positive Western blot detection has been specifically confirmed in mouse testis tissue, PC-3 cells, and rat testis tissue . For immunohistochemistry, positive results have been documented in mouse heart tissue using recommended antigen retrieval conditions with TE buffer pH 9.0 or alternatively with citrate buffer pH 6.0 . Researchers should verify cross-reactivity when working with samples from other species not explicitly listed in validation data.

What are the optimal protocols for Western blot detection of SYNPO2L?

For successful Western blot detection of SYNPO2L:

• Prepare protein lysates from tissues or cells of interest using standard RIPA buffer supplemented with protease inhibitors

• Load 20-50μg total protein per lane for separation by SDS-PAGE (8-10% gel recommended)

• Transfer proteins to PVDF or nitrocellulose membrane

• Block with 5% non-fat milk in TBST for 1 hour at room temperature

• Incubate with SYNPO2L antibody at 1:500-1:3000 dilution in blocking buffer overnight at 4°C

• Wash membrane with TBST (3×10 minutes)

• Incubate with appropriate HRP-conjugated secondary antibody for 1 hour at room temperature

• Visualize using enhanced chemiluminescence

The expected molecular weight for SYNPO2L is approximately 79 kDa, though the calculated weight is 102 kDa (977 amino acids) . This discrepancy should be considered when interpreting results.

How should immunohistochemistry with SYNPO2L antibody be performed?

For IHC detection of SYNPO2L in tissue sections:

• Prepare formalin-fixed, paraffin-embedded tissue sections (4-6μm thickness)

• Deparaffinize and rehydrate sections through xylene and graded alcohols

• Perform antigen retrieval, preferably using TE buffer pH 9.0 (heat-mediated), or alternatively citrate buffer pH 6.0

• Block endogenous peroxidase activity with 3% H₂O₂ in methanol

• Block non-specific binding with 5% normal serum in PBS

• Incubate with SYNPO2L antibody at 1:50-1:500 dilution overnight at 4°C

• Apply appropriate secondary antibody and detection system

• Counterstain, dehydrate, and mount

Optimization of antibody concentration is critical, as is the inclusion of positive controls (mouse heart tissue is recommended) and negative controls (primary antibody omission) .

What considerations are important for immunofluorescence applications of SYNPO2L antibody?

For optimal immunofluorescence results:

• Culture cells on coverslips or prepare tissue cryosections

• Fix with 4% paraformaldehyde for 15 minutes at room temperature

• Permeabilize with 0.2% Triton X-100 in PBS for 10 minutes

• Block with 5% normal serum in PBS for 1 hour

• Incubate with SYNPO2L antibody at 1:200-1:800 dilution overnight at 4°C

• Wash with PBS (3×5 minutes)

• Incubate with fluorophore-conjugated secondary antibody for 1 hour at room temperature

• Counterstain nuclei with DAPI

• Mount with anti-fade mounting medium

SYNPO2L has been successfully detected in HepG2 cells using immunofluorescence . For co-localization studies, consider double-staining with actin markers as SYNPO2L is an actin-associated protein .

How is SYNPO2L involved in cancer progression mechanisms?

Recent research demonstrates SYNPO2L's significant role in cancer progression through multiple mechanisms:

• Metastasis promotion: SYNPO2L has been identified as a core gene regulated by m6A modification, correlating with adverse prognosis and metastasis in colorectal cancer patients .

• Tumor microenvironment modulation: SYNPO2L promotes the secretion of COL10A1 and infiltration of tumor-associated fibroblasts, facilitating Epithelial-Mesenchymal Transition (EMT) in tumor cells, making them more prone to distant metastasis .

• Growth regulation: In vitro and in vivo studies demonstrate that SYNPO2L knockdown significantly inhibits tumor cell proliferation and migration, while overexpression promotes tumor growth .

• Prognostic marker: High SYNPO2L expression correlates with poor disease-specific survival and increased local recurrence in cancer patients .

When investigating SYNPO2L in cancer research, antibody selection should prioritize those validated in relevant tumor models, and experimental designs should account for tumor heterogeneity and microenvironment factors.

What is the relationship between SYNPO2L and m6A RNA modification?

SYNPO2L mRNA stability is regulated by the m6A writer METTL16 through a complex regulatory mechanism:

• METTL16 regulates SYNPO2L mRNA stability through interaction with the m6A reader YTHDC1 .

• YTHDC1 shows the highest correlation with SYNPO2L expression among m6A readers and writers (R=0.411, P<0.001) .

• Overexpression of YTHDC1 significantly increases SYNPO2L mRNA levels and stability, while knockdown suppresses expression and reduces stability .

• The SYNPO2L gene contains specific METTL16 binding sites; mutation of these sites eliminates the regulatory effect of METTL16 .

Researchers investigating this relationship should consider designing experiments that manipulate m6A writers and readers, particularly METTL16 and YTHDC1, to observe effects on SYNPO2L expression and function. Luciferase reporter assays using wild-type and mutated SYNPO2L constructs can help validate specific m6A modification sites .

How does SYNPO2L interact with the actin cytoskeleton and signal transduction pathways?

SYNPO2L functions as an actin-associated protein involved in:

• Modulation of actin-based cellular morphology .

• Positive regulation of Rho protein signal transduction .

• Positive regulation of stress fiber assembly .

To study these interactions, researchers should consider:

• Co-immunoprecipitation experiments to identify SYNPO2L's binding partners

• Cytoskeletal fractionation assays to determine SYNPO2L's distribution between soluble and insoluble fractions

• Live-cell imaging using fluorescently-tagged SYNPO2L constructs to visualize dynamics

• Rho activity assays when manipulating SYNPO2L expression levels

• Stress fiber visualization using phalloidin staining in conjunction with SYNPO2L immunofluorescence

The relationship between SYNPO2L and Rho signaling suggests potential involvement in mechanical force sensing and cellular responses to extracellular matrix stiffness, presenting opportunities for mechanobiology research.

What are common issues encountered with SYNPO2L antibodies and how can they be resolved?

Researchers frequently encounter several challenges when working with SYNPO2L antibodies:

• Multiple or unexpected bands in Western blot:

  • Verify sample preparation (complete protein denaturation)

  • Test different blocking agents (5% BSA may reduce background compared to milk)

  • Optimize primary antibody concentration (start with 1:1000 dilution)

  • Consider post-translational modifications or protein degradation

  • Validate with positive controls (mouse testis tissue shows reliable detection)

• Weak or absent signal in IHC/IF:

  • Optimize antigen retrieval (TE buffer pH 9.0 is recommended for SYNPO2L)

  • Test longer primary antibody incubation times (overnight at 4°C)

  • Increase antibody concentration (1:50-1:200 for challenging samples)

  • Use amplification systems for low-abundance targets

  • Verify tissue fixation conditions (overfixation can mask epitopes)

• High background:

  • Implement additional blocking steps (add 0.1-0.3% Triton X-100 to blocking buffer)

  • Increase washing duration and frequency

  • Reduce secondary antibody concentration

  • Use more specific secondary antibodies

How should researchers validate SYNPO2L antibody specificity?

Thorough validation of SYNPO2L antibody specificity is crucial for reliable results:

• Positive controls: Include tissues with known SYNPO2L expression (mouse testis, heart tissue, PC-3 cells) .

• Genetic validation: Compare antibody signal in wild-type versus SYNPO2L knockdown or knockout models .

• Peptide competition: Pre-incubate antibody with immunizing peptide to confirm specific binding.

• Multiple antibody comparison: Use antibodies targeting different SYNPO2L epitopes to confirm consistent detection patterns.

• Orthogonal techniques: Verify protein expression with complementary methods (qPCR, mass spectrometry).

• Cross-reactivity assessment: Test antibody against related proteins (e.g., other synaptopodin family members) to confirm specificity.

When publishing research using SYNPO2L antibodies, detailed validation methods should be described to enhance reproducibility.

What considerations are important when studying SYNPO2L in cancer models?

When investigating SYNPO2L in cancer research:

• Sample selection: Consider the heterogeneity of expression across different cancer types; SYNPO2L overexpression has been documented in nasopharyngeal carcinoma and colorectal cancer .

• Expression correlation: Analyze correlation between SYNPO2L expression and clinical parameters (stage, metastasis status, survival) .

• Functional studies design:

  • Use both knockdown and overexpression approaches for comprehensive understanding

  • Consider both in vitro (cell proliferation, migration, colony formation) and in vivo (xenograft) models

  • Evaluate effects on tumor microenvironment, particularly cancer-associated fibroblasts

• Mechanism exploration:

  • Investigate m6A regulation of SYNPO2L through METTL16 and YTHDC1

  • Examine downstream effects on COL10A1 expression and EMT markers

  • Analyze Rho signaling pathway activation

• Technical considerations:

  • Include appropriate controls for antibody specificity

  • Use multiple cell lines to account for biological variability

  • Consider tumor microenvironment interactions in experimental design

What emerging applications of SYNPO2L antibodies should researchers consider?

As SYNPO2L research evolves, several promising applications are emerging:

• Prognostic biomarker development: SYNPO2L expression correlates with poor prognosis in certain cancers, suggesting potential as a clinical biomarker . Researchers should consider developing standardized IHC protocols for consistent clinical evaluation.

• Therapeutic target validation: Given SYNPO2L's role in tumor growth and metastasis , antibodies may be useful for validating it as a therapeutic target through neutralization experiments or for developing therapeutic antibodies.

• Single-cell analysis: Combining SYNPO2L antibodies with single-cell technologies could reveal expression heterogeneity within tumors and identify specific cellular subpopulations with metastatic potential.

• Live-cell imaging: Development of non-interfering anti-SYNPO2L antibody fragments for live-cell applications could provide insights into dynamic protein localization during cell migration and division.

• Liquid biopsy development: Investigating SYNPO2L in circulating tumor cells might yield novel minimally invasive diagnostic approaches.

Future applications may benefit from newer antibody formats (e.g., nanobodies, recombinant antibodies) with enhanced specificity and reduced batch-to-batch variation.

How can researchers integrate SYNPO2L analysis with other molecular markers?

For comprehensive understanding of SYNPO2L in biological contexts:

• Co-expression analysis with cytoskeletal markers: Combine SYNPO2L antibodies with markers for actin (phalloidin), focal adhesions (paxillin, vinculin), and Rho-GTPases to understand spatial relationships .

• Multi-omics integration: Correlate SYNPO2L protein expression (antibody-based) with:

  • Transcriptomic data (RNA-seq)

  • Epigenetic modifications (particularly m6A methylation status)

  • Proteomic profiles of interacting partners

• Signaling pathway analysis: Combine SYNPO2L detection with phospho-specific antibodies targeting Rho-effector pathways to establish functional relationships.

• Tumor microenvironment assessment: Multiplex immunofluorescence using SYNPO2L antibodies alongside markers for cancer-associated fibroblasts (α-SMA), extracellular matrix components (COL10A1), and EMT markers can provide spatial context for SYNPO2L's role in metastasis .

• Clinical correlation panels: Develop antibody panels combining SYNPO2L with established prognostic markers to enhance predictive power in patient stratification.

What technological advances might improve SYNPO2L antibody applications?

Emerging technologies promise to enhance SYNPO2L antibody utility:

• Super-resolution microscopy: Techniques like STORM and PALM combined with highly specific SYNPO2L antibodies can reveal nanoscale organization of SYNPO2L relative to cytoskeletal structures.

• Proximity labeling: BioID or APEX2 fusions with SYNPO2L could identify transient interaction partners when combined with specific antibodies for validation.

• Antibody engineering: Development of recombinant anti-SYNPO2L antibodies with standardized production methods would improve reproducibility over traditional polyclonal antibodies .

• Multiplex imaging technologies: Methods like Imaging Mass Cytometry or CODEX using anti-SYNPO2L antibodies could provide spatial context within complex tissues.

• Automated image analysis: Machine learning algorithms applied to SYNPO2L immunostaining could quantify expression patterns across large tissue cohorts with reduced subjective bias.

• In vivo imaging applications: Development of near-infrared fluorophore-conjugated SYNPO2L antibodies or fragments for non-invasive tracking of SYNPO2L-expressing tumors in preclinical models.